Filing Details

Accession Number:
0001140361-11-011228
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-02-22 17:26:00
Reporting Period:
2011-02-17
Filing Date:
2011-02-22
Accepted Time:
2011-02-22 17:26:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1389046 F James Polewaczyk One Idexx Drive
Westbrook ME 04092
Corporate Vice President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-02-17 5,265 $56.95 8,272 No 4 M Direct
Common Stock Acquisiton 2011-02-17 8,000 $34.37 16,272 No 4 M Direct
Common Stock Acquisiton 2011-02-17 2,000 $53.31 18,272 No 4 M Direct
Common Stock Acquisiton 2011-02-17 3,603 $56.95 21,875 No 4 M Direct
Common Stock Disposition 2011-02-17 12,000 $77.58 9,875 No 4 S Direct
Common Stock Disposition 2011-02-17 5,236 $77.66 4,639 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (right to buy) Disposition 2011-02-17 5,265 $0.00 5,265 $56.95
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2011-02-17 8,000 $0.00 8,000 $34.37
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2011-02-17 2,000 $0.00 2,000 $53.31
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2011-02-17 3,603 $0.00 3,603 $56.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,510 2015-02-13 No 4 M Direct
9,837 2016-02-13 No 4 M Direct
9,657 2017-02-13 No 4 M Direct
2,401 2015-02-13 No 4 M Direct
Footnotes
  1. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.50 to $77.72, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
  2. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.63 to $77.695, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
  3. Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2009) of the date of grant.
  4. Grant of options to buy shares of common stock becomes exercisable as to 4,149 shares on 02/14/2010, 02/14/2011, 02/14/2012, 02/14/2013, and the remaining 1,241 shares on 02/14/2014.
  5. Grant of options to buy shares of common stock becomes exercisable as to 2,707 shares on 02/14/2011 and 02/14/2012, 2,706 shares on 02/14/2013 and 02/14/2014, and the remaining 831 shares on 02/14/2015.
  6. Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2009) of the date of grant.